Wells Fargo Starts Ardea Biosciences (RDEA) at Market Perform; Gout Market Represents A Large Opportunity
Tweet Send to a FriendGet Alerts RDEA Hot Sheet
Price: $31.96 --0%
Rating Summary:
7 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
7 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade RDEA Now!
Wells Fargo initiates coverage on Ardea Biosciences (NASDAQ: RDEA) with a Market Perform. PT range $16-$20.
Wells analyst says, "We believe RDEA's lead drug, lesinurad, has the potential to change the gout treatment paradigm, providing an efficacious add-on for patients not responsive to or intolerant to the current gold-standard, allopurinol, or for those with severe disease. We believe the agent has considerable promise; however, the gout market remains immature for new branded therapies, lesinurad's long-term safety is unknown, and near-term news flow is limited. As such, we believe RDEA's valuation fairly balances the potential and risks of lesinurad and we expect shares to trade in line with the sector, although we would look at the stock again closer to the phase III data readout."
For an analyst ratings summary and ratings history on Ardea Biosciences click here. For more ratings news on Ardea Biosciences click here.
Shares of Ardea Biosciences closed at $17.03 yesterday, with a 52 week range of $13.15-$30.61.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Wells analyst says, "We believe RDEA's lead drug, lesinurad, has the potential to change the gout treatment paradigm, providing an efficacious add-on for patients not responsive to or intolerant to the current gold-standard, allopurinol, or for those with severe disease. We believe the agent has considerable promise; however, the gout market remains immature for new branded therapies, lesinurad's long-term safety is unknown, and near-term news flow is limited. As such, we believe RDEA's valuation fairly balances the potential and risks of lesinurad and we expect shares to trade in line with the sector, although we would look at the stock again closer to the phase III data readout."
For an analyst ratings summary and ratings history on Ardea Biosciences click here. For more ratings news on Ardea Biosciences click here.
Shares of Ardea Biosciences closed at $17.03 yesterday, with a 52 week range of $13.15-$30.61.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Wunderlich Securities Starts Vertex Energy (VTNR) at Buy
- Barclays Starts Verizon Communications (VZ) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
